Satellos Shows 3.7% Fat Fraction Drop, 34% Effort Gain and 38% CK Reduction
MSLE•Satellos’ six-month TRAILHEAD data in four adults with Duchenne muscular dystrophy showed a mean 3.7% decline in muscle fat fraction (from 49.7% to 46.0%) and a 34% increase in upper limb effort (from 16.1 to 21.6 joules/kg). Mean creatine kinase levels fell by 38% and near-doubled handgrip strength remained stable, with no serious adverse events.
1. Six-Month TRAILHEAD Interim Data
In four adults aged 21–28 with Duchenne muscular dystrophy, treatment with SAT-3247 yielded a mean 3.7% reduction in muscle fat fraction (from 49.7% at baseline to 46.0% at month 6) and a 34% increase in maximum upper limb effort (from 16.1 to 21.6 joules/kg). Handgrip strength near-doubled during the initial 28-day study and remained stable through six months of follow-up.
2. Safety and Biomarker Improvements
SAT-3247 was well tolerated with 100% compliance over an average of 186 days and no serious treatment-emergent adverse events or discontinuations. Mean creatine kinase, a marker of muscle damage, declined 38% from 2,130 u/l at baseline to 1,315 u/l at month 6.
3. Progression to Pediatric BASECAMP Trial
Satellos remains on track to complete enrollment in the BASECAMP trial for pediatric DMD and plans to initiate U.S. clinical sites for the TRAILHEAD study in the third quarter. The company will host a conference call today at 8:30 a.m. ET to review these data and discuss next steps.
